Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Cardiac Injury Predicts Mortality in COVID-19 Patients

By HospiMedica International staff writers
Posted on 06 Apr 2020
A new study shows that mortality among COVID-19 patients with cardiac injury is more than ten times higher than is those without cardiac injury. More...


Researchers at Renmin Hospital (Wuhan, China) and Wuhan University (China) conducted a cohort study of 416 consecutive patients (median age 64 years, 50.7% female) with confirmed COVID-19 between January 20, 2020 and February 10, 2020. Clinical, laboratory, radiological, and treatment data were collected and analyzed, and the outcomes of patients with and without cardiac injury were compared in order to analyze association with mortality. Fever was the most common clinical symptom (80.3%), followed by cough (34.6%) and shortness of breath (28.1%).

The results showed that patients with cardiac injury had higher mortality (51.2%) than those without cardiac injury (4.5%). The 82 patients (19.7%) found to have cardiac injury were older (median 74 years of age) and had more comorbidities, such as hypertension and coronary heart disease (CAD). In addition, 22% of the patients with cardiac injury required mechanical ventilation, compared to just 4.2% in those without cardiac injury. The incidence of acute respiratory distress syndrome (ARDS) was 58.5% and 14.7%, respectively. The study was published on March 25, 2020, in JAMA Cardiology.

“Cardiac injury is a common condition among hospitalized patients with COVID-19 in Wuhan, China, and it is associated with higher risk of in-hospital mortality,” concluded lead author Shaobo Shi, MD, of Renmin Hospital, and colleagues. “On the basis of the present results, we can only estimate the severity of cardiac injury. Thus, because of the current limited evidence, the question of whether the SABRS-CoV-2 virus can directly injure the heart requires further demonstration.”

Since December 2019, COVID-19 has resulted in considerable morbidity and mortality worldwide. Severe respiratory distress is considered the main cause of coronavirus-induced death, and severe pneumonia is independently associated with admission to an intensive care unit (ICU), mechanical ventilation, or death. Emerging studies show that patients with cardiac injury present with more severe acute illness, manifested by abnormal laboratory and radiographic findings, such as higher levels of CRP, NT-proBNP, and creatinine levels; and more multiple mottling and ground-glass opacity on CT.

Related Links:
Renmin Hospital
Wuhan University



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammography System (Analog)
MAM VENUS
Emergency Ventilator
Shangrila935
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.